[Subthalamic stimulation in a patient with multiple system atrophy: a clinicopathological report].
BACKGROUND
Efficacy of high frequency subthalamic nucleus (STN) stimulation has been demonstrated in idiopathic Parkinson's disease (IPD). However, since it may be difficult to differentiate IPD from multiple system atrophy with parkinsonian presentation (MSA-P), a few cases of MSA-P has been treated by deep brain stimulation (DBS) and showed no sustained improvement of clinical signs. We report a patient with a clinical misdiagnosed MSA-P, later confirmed by neuropathological study, who was improved by DBS for one year.


METHODS
A 63-year-old parkinsonian patient had been treated by levodopa for 6 years with a persistent good response. Over one year he progressively developed disabling fluctuations with severe axial syndrome and vegetative non motor symptoms in off periods. After checking usual contraindications, he was included in surgical procedure protocol (bilateral STN stimulation). During the first year after surgery, the clinical status improved with disappearance of non motor fluctuations, a 45 percent decrease of the OFF UPDRS III score, and a 39 percent reduction of the treatment. However after one year, axial symptoms reappeared with recurrent falls, as well as increasing dysarthry and swallowing difficulties which were only slightly improved by levodopa. He developed severe urinary disorders increased by a prostatic adenoma which led to surgical treatment. During the post operative period, 2 years after DBS, he died suddenly from an unexplained cause. A cerebral autopsy was performed and showed a good position of the two electrodes in the STN. Microscopic studies revealed severe neuronal depletion in the substantia nigra but no Lewy bodies. Immunohistochemical methods demonstrated numerous argyrophilic glial cytoplasmic inclusions positive for alpha-synuclein and ubiquitin in the STN, putamen, globus pallidus, pontine nuclei and cerebellar white matter, significant of MSA.


CONCLUSIONS
This case shows that DBS can improve parkinsonian signs in MSA-P with persistent dopa sensitivity. However, probably because of striatal degeneration progression, this improvement is time limited and STN DBS cannot be recommended in MSA.
Talmant
V
V
Département de Neurologie, Hôpital Civil, CHU, Strasbourg.
Esposito
P
P
Stilhart
B
B
Mohr
M
M
Tranchant
C
C
D000236:Adenoma / Q000601:surgery; D000978:Antiparkinson Agents / Q000627:therapeutic use; D015415:Biomarkers; D001921:Brain / Q000473:pathology; D001923:Brain Chemistry; D003131:Combined Modality Therapy; D046690:Deep Brain Stimulation; D003951:Diagnostic Errors; D018450:Disease Progression; D017809:Fatal Outcome; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000601:surgery; D013378:Substantia Nigra / Q000473:pathology; D020531:Subthalamic Nucleus / Q000503:physiopathology; D025801:Ubiquitin / Q000032:analysis; D051844:alpha-Synuclein / Q000032:analysis
D000978:Antiparkinson Agents; D015415:Biomarkers; D025801:Ubiquitin; D051844:alpha-Synuclein; D007980:Levodopa